Loading...
Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: A randomized trial
Date
2020
Abstract
Rationale & Objective: Hyperuricemia has been implicated in the development and progression of chronic kidney disease. Verinurad is a novel, potent, specific urate reabsorption inhibitor. We evaluated the effects on albuminuria of intensive urate-lowering therapy with verinurad combined with the xanthine oxidase inhibitor febuxostat in patients with hyperuricemia and type 2 diabetes mellitus (T2DM). Study Design: Phase 2, multicenter, prospective, randomized, double-blind, parallel-group, placebo-controlled trial. Setting & Participants: Patients 18 years or older with hyperuricemia, albuminuria, and T2DM. Intervention: Patients randomly assigned 1:1 to verinurad (9 mg) plus febuxostat (80 mg) or matched placebo once daily for 24 weeks. Outcomes: The primary end point was change in urinary albumin-creatinine ratio (UACR) from baseline after 12 weeks’ treatment. Secondary end points included safety and tolerability and effect on glomerular filtration.
Supervisor
Description
peer-reviewed
Publisher
Elsevier
Citation
American Journal of Kidney Diseases(AJKD);77(4), pp.481-489.
Collections
Files
Loading...
Stack_2020_Effect.pdf
Adobe PDF, 499.16 KB
Keywords
ULRR Identifiers
Funding code
Funding Information
AstraZeneca, Health Research Board (HRB)